Breaking News Instant updates and real-time market news.

MOH

Molina Healthcare

$66.80

-3.2 (-4.57%)

, UNH

UnitedHealth

$191.81

0.66 (0.35%)

18:14
07/31/17
07/31
18:14
07/31/17
18:14

Rand Paul says Trump considering executive action on healthcare, Reuters says

U.S. Republican Senator Rand Paul said he spoke to President Donald Trump about healthcare reform and said that the president was weighing taking some form of executive action to address issues with the healthcare system following the Senate's failed efforts to pass a bill to reform the system, Reuters reports. Paul told Trump that he felt the president had the authority to form associations that would allow organizations to offer group health insurance plans, the report notes. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Reference Link

MOH

Molina Healthcare

$66.80

-3.2 (-4.57%)

UNH

UnitedHealth

$191.81

0.66 (0.35%)

CNC

Centene

$79.42

-3.27 (-3.95%)

WCG

WellCare

$176.99

-2.97 (-1.65%)

CI

Cigna

$173.56

-0.41 (-0.24%)

ANTM

Anthem

$186.21

-1.58 (-0.84%)

HNT

Health Net

HUM

Humana

$231.20

-1.88 (-0.81%)

AET

Aetna

$154.31

-0.98 (-0.63%)

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 04

    Aug

  • 04

    Aug

  • 14

    Aug

  • 26

    Sep

  • 27

    Sep

MOH Molina Healthcare
$66.80

-3.2 (-4.57%)

07/25/17
LEER
07/25/17
NO CHANGE
Target $80
LEER
Outperform
Leerink remains bullish on Molina Healthcare after job cut announcement
Leerink analyst Ana Gupte continues to have "strong conviction" on Molina Healthcare and reiterates an Outperform rating and a $80 price target after the company's announcement from its interim CEO and CFO Joseph White on the elimination of 1,400 jobs, or 10% of its corporate and health plan workforce. The analyst estimates this could expand margins by over 50 bps or offer 50% net margin expansion and get the company by the end of September to the low end of the stated target of 1.5%-2% net margins.
06/14/17
LEER
06/14/17
NO CHANGE
Target $80
LEER
Outperform
Molina Healthcare price target raised to $80 from $70 at Leerink
Leerink analyst Ana Gupte raised her price target for Molina Healthcare shares to $80 and remains "bullish" on the name after a call with CFO and interim CEO Joseph White. The analyst says White aligned with her view that the upcoming re-procurement of State Medicaid contracts "does not pose meaningful downside risk." Further, she learned the CEO search is making good progress with an "attractive slate" of senior executives with Managed Care experience. The analyst keeps an Outperform rating on Molina.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
UNH UnitedHealth
$191.81

0.66 (0.35%)

06/27/17
KEYB
06/27/17
DOWNGRADE
KEYB
Sector Weight
LabCorp downgraded on potential acquisition at KeyBanc
As noted earlier, KeyBanc downgraded LabCorp to Sector Weight from Overweight. Analyst Donald Hooker downgraded the stock based on his belief that the company implied that it may make an "expensive" deal to acquire a contract research organization. The analyst adds that the upcoming renewal of the company's contract with UnitedHealth (UNH) in 2H18 creates uncertainty.He expects to hear news about the deal "in coming months."
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $200
FBCO
Outperform
UnitedHealth price target raised to $200 from $195 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for UnitedHealth to $200 from $195 ahead of Q2 results. He reiterates an Outperform rating on the shares.
CNC Centene
$79.42

-3.27 (-3.95%)

06/06/17
MSCO
06/06/17
INITIATION
Target $86
MSCO
Overweight
Centene initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Centene with an Overweight and a $86 price target. The analyst thinks the HealthNet acquisition provides diversification and entry planned expansion in Medicare Advantage could offset potential headwinds.
07/11/17
BERN
07/11/17
NO CHANGE
BERN
Centene price target raised to $100 from $85 at Bernstein
Bernstein analyst Lance Wilkes raised his price target on Centene based on his belief that the managed Medicaid market will grow over the long-term, particularly in long-term care. He keeps an Outperform rating on the stock.
07/26/17
PIPR
07/26/17
NO CHANGE
Target $105
PIPR
Overweight
Piper says double down on Centene, ups target to $105
Piper Jaffray analyst Sarah James attributes yesterday's post-earnings pullback in shares of Centene to the macro backdrop and the company's spending bump that she believes fuels the bear concern that constant spending for growth pressures margins. The analyst "strongly" disagrees and believe this is when investors should double down on Centene shares. The company will see the greatest multiple expansion in the group and has the highest potential for earnings upside, James tells investors in a research note. She raised her price target for the shares to $105 from $85 and keeps an Overweight rating on the name.
WCG WellCare
$176.99

-2.97 (-1.65%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $163
FBCO
Neutral
WellCare price target raised to $163 from $155 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for WellCare to $163 from $155 ahead of Q2 results. He reiterates a Neutral rating on the shares.
06/06/17
MSCO
06/06/17
INITIATION
Target $183
MSCO
Equal Weight
WellCare initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated WellCare with an Equal Weight rating and $183 price target, citing its current valuation.
CI Cigna
$173.56

-0.41 (-0.24%)

06/16/17
06/16/17
NO CHANGE

Leerink reiterates view that Cigna could bid for Humana
Leerink analyst Ana Gupte reiterated his views that Cigna (CI) could make a bid Humana (HUM) following Cigna's disclosure that 60% of its Medicare Advantage plans will be in 4-STAR rated plans. The announcement is most positive for Humana (HUM) which is the largest pure play Medicare Advantage name, but also paves the way for Cigna to potentially dievest its legacy HS Medicare Advantage book and bid for Humana.
07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
ANTM Anthem
$186.21

-1.58 (-0.84%)

06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
HNT Health Net

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$231.20

-1.88 (-0.81%)

06/28/17
SBSH
06/28/17
INITIATION
Target $275
SBSH
Buy
Humana initiated with a Buy at Citi
Citi analyst Ralph Giacobbe started Humana with a Buy rating and $275 price target. The company has built a "strong and coveted" Medicare Advantage franchise that should deliver "strong" growth, the analyst contends. He also believes a potential takeout will provide valuation support.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $250
FBCO
Outperform
Humana price target raised to $250 from $245 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $250 from $245 ahead of Q2 results. He reiterates an Outperform rating on the shares.
AET Aetna
$154.31

-0.98 (-0.63%)

07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$33.17

-0.19 (-0.57%)

13:30
08/17/17
08/17
13:30
08/17/17
13:30
Hot Stocks
Pfizer lymphoblastic leukemia treatment approved by FDA with boxed warning »

The FDA approved today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

WIN

Windstream

$2.01

0.11 (5.79%)

13:30
08/17/17
08/17
13:30
08/17/17
13:30
Options
Call buyers in Windstream as shares lose ground »

Call buyers in Windstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
08/17/17
08/17
13:30
08/17/17
13:30
General news
NY Fed's overnight reverse repo totaled $78.6 B with 30 counterparties »

NY Fed's overnight…

13:30
08/17/17
08/17
13:30
08/17/17
13:30
General news
Breaking General news story  »

Minneapolis Federal…

WERN

Werner

$30.95

-0.1 (-0.32%)

13:27
08/17/17
08/17
13:27
08/17/17
13:27
Hot Stocks
Werner CEO says business has been improving throughout the year »

The trucking firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:25
08/17/17
08/17
13:25
08/17/17
13:25
General news
U.S. VIX equity volatility surged 26% to 14.88 highs »

U.S. VIX equity…

13:25
08/17/17
08/17
13:25
08/17/17
13:25
Conference/Events
SEC holds a closed commission meeting »

Closed Commission Meeting…

WMT

Wal-Mart

$79.18

-1.7998 (-2.22%)

13:24
08/17/17
08/17
13:24
08/17/17
13:24
Recommendations
Wal-Mart analyst commentary  »

Wal-Mart posted good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

ADP

ADP

$111.10

-0.48 (-0.43%)

13:21
08/17/17
08/17
13:21
08/17/17
13:21
Recommendations
ADP analyst commentary  »

ADP will have difficulty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

NAK

Northern Dynasty

$1.56

0.065 (4.36%)

13:20
08/17/17
08/17
13:20
08/17/17
13:20
Options
Call buyers back in Northern Dynasty Minerals »

Call buyers back in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.55

-0.035 (-0.30%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Upgrade
Celestica rating change  »

Follow-up: Celestica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

, AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Hot Stocks
Breaking Hot Stocks news story on Tesaro, AstraZeneca »

Tesaro drops 2% after FDA…

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

$NSD

NASDAQ Market Internals

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.11

-0.07 (-0.24%)

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Hot Stocks
FDA posts approval of new dosage form for AstraZeneca's Lynparza 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 08

    Sep

$NYE

NYSE Market Internals

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:13
08/17/17
08/17
13:13
08/17/17
13:13
Hot Stocks
CenturyLink says working to finalize Level 3 deal by end of Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:12
08/17/17
08/17
13:12
08/17/17
13:12
Hot Stocks
Breaking Hot Stocks news story on CenturyLink, Level 3 »

CenturyLink says working…

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

13:10
08/17/17
08/17
13:10
08/17/17
13:10
Options
ADP attracts put buyers as shares come under fire »

ADP attracts put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADOM

Adomani

$12.86

0.86 (7.17%)

, VLKAY

Volkswagen

$31.10

0.19 (0.61%)

13:06
08/17/17
08/17
13:06
08/17/17
13:06
Hot Stocks
Adomani sees $2.9B in settlement funds from Volkswagen »

Adomani (ADOM) announced…

ADOM

Adomani

$12.86

0.86 (7.17%)

VLKAY

Volkswagen

$31.10

0.19 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.89

-0.05 (-0.42%)

13:05
08/17/17
08/17
13:05
08/17/17
13:05
Options
Horizon Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.50

-0.08 (-0.69%)

13:04
08/17/17
08/17
13:04
08/17/17
13:04
Upgrade
Celestica rating change  »

Celestica upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$0.95

0.05 (5.56%)

12:55
08/17/17
08/17
12:55
08/17/17
12:55
Hot Stocks
Medovex names Charlie Farrahar as CFO »

Medovex reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$33.20

-0.16 (-0.48%)

12:53
08/17/17
08/17
12:53
08/17/17
12:53
Hot Stocks
FDA posts approval of Pfizer's biologic license qpplication for Besponsa 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

NADL

North Atlantic Drilling

$1.44

-0.075 (-4.97%)

12:50
08/17/17
08/17
12:50
08/17/17
12:50
Options
Notable put spread in North Atlantic Drilling »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

12:45
08/17/17
08/17
12:45
08/17/17
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.